Rapid and Reproducible RP-HPLC Method for Stability and Assay Determination of Enmetazobactam
Introduction:Enmetazobactam is a next-generation diazabicyclooctane (DBO) β-lactamase inhibitor that lacks a β-lactam ring yet effectively restores the antibacterial activity of β-lactam antibiotics, particularly cefepime, against extended-spectrum β ...
Himanchal
core +1 more source
Antimicrobial Resistance in the Post-Antibiotic Era: Molecular Mechanisms, Emerging Therapeutics, and Evidence-Based Stewardship Implementation in Latin America: Desafíos Contemporáneos y Estrategias Terapéuticas Innovadoras en la Era Post-Antibiótica [PDF]
Objetivo: Analizar los mecanismos moleculares de resistencia antimicrobiana, estrategias terapéuticas emergentes, y enfoques preventivos basados en evidencia actual, con énfasis particular en la situación epidemiológica en América Latina y Colombia.
Ostos Ortiz, Olga Lucia +1 more
core +1 more source
Exblifep, a new antibacterial for the treatment of urinary tract infections and pyelonephritis
Antibiotic resistance is an ever-present threat that demands constant innovations in order to treat urinary tract infections and pyelonephritis. Bacteria are known to develop various adaptations in order to evade eradication by antibiotic agents. In this
Clark, Leonard +3 more
core +1 more source
DEVELOPMENT AND VALIDATION OF HPLC METHOD FOR THE ESTIMATION OF ANTIMICROBIAL DRUGS IN COMBINED DOSAGE FORM [PDF]
A simple, precise, accurate, and robust reverse-phase high-performance liquid chromatography (RP-HPLC) method was developed and validated for the simultaneous estimation of Enmetazobactam (EZB) and Cefepime (CFP) in combined dosage form.
Shefali Arora +3 more
core
P59 Focus on enmetazobactam chemical stability in association with cefepime for prolonged infusions, in syringe and elastomeric diffusers [PDF]
Abstract Background Enmetazobactam, a N-methylated tazobactam derivative is a novel extended-spectrum β-lactamase inhibitor with a unique mechanism that overcomes tazobactam-resistant variants of class A β-lactamases, and is the first β-lactamase inhibitor approved in combination with cefepime in both
Ward, Jon +4 more
europepmc +2 more sources
Efficacy of Cefepime/Enmetazobactam (Cipenmet) in Piperacillin‑Tazobactam Resistant Urinary Tract Infections: A Cross‑Sectional Study [PDF]
Introduction: Urinary tract infections (UTIs) are among the most common bacterial infections, with rising resistance to conventional antimicrobials such as piperacillin tazobactam.
Shivani B. Hambarde
core
La FDA y la EMA aprueban EXBLIFEP® para tratar infecciones urinarias complicadas
El nuevo antibiótico, una combinación de cefepima y enmetazobactam, ha sido autorizado en 2024 para combatir infecciones urinarias causadas por bacterias multirresistentes en ...
Valverde Urrea, Miguel
core
Sphingobacterium spp. as intrinsic producers of SPI Ambler class B metallo-β-lactamases
International audienceObjectives: To characterize the intrinsic carbapenemase of Sphingobacterium spp.Materials and methods: Sphingobacterium spp. clinical isolates (n = 63) were collected in several French laboratories from 2012 to 2022.
Bille, Emmanuelle +16 more
core +1 more source
Synergistic activity of cefepime/enmetazobactam with meropenem, piperacillin, piperacillin/tazobactam, cefiderocol and fosfomycin against Klebsiella pneumoniae carrying blaKPC allelic variants. [PDF]
Crema A +3 more
europepmc +1 more source
Antibiotic development and a path to access in India. [PDF]
Manesh A +4 more
europepmc +1 more source

